Compass Pathways appoints Dr. Jeffrey Jonas to board; Thomas Lönngren to retire Dec 31, 2025

COMPASS Pathways plc

Dr. Jonas appointed Board effective Oct 29, 2025; Class II director, audit and scientific committees.
Initial option for 52,000 ordinary shares vesting over 3 yrs; annual retainers $40k board, $10k audit, $6k scientific.
Thomas Lönngren to retire Dec 31, 2025 after 6+ years; no disagreements.
Dr. Jonas brings 30+ yrs neuroscience leadership; former CEO of Sage Therapeutics, partner at Cure Ventures.
Changes align with advancing COMP360 program and potential commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.